Large-scale human tissue analysis identifies Uroplakin 1b as a putative diagnostic marker in surgical pathology

TY - JOUR

T1 - Large-scale human tissue analysis identifies Uroplakin 1b as a putative diagnostic marker in surgical pathology

AU - Reiswich, Viktor

AU - Akdeniz, Gonca

AU - Lennartz, Maximilian

AU - Menz, Anne

AU - Chirico, Viktoria

AU - Hube-Magg, Claudia

AU - Fraune, Christoph

AU - Bernreuther, Christian

AU - Simon, Ronald

AU - Clauditz, Till S

AU - Sauter, Guido

AU - Uhlig, Ria

AU - Hinsch, Andrea

AU - Kind, Simon

AU - Jacobsen, Frank

AU - Möller, Katharina

AU - Steurer, Stefan

AU - Minner, Sarah

AU - Burandt, Eike

AU - Marx, Andreas H

AU - Lebok, Patrick

AU - Krech, Till

AU - Dum, David

N1 - Copyright © 2022. Published by Elsevier Inc.

PY - 2022/8

Y1 - 2022/8

N2 - Uroplakin 1B (Upk1b) stabilizes epithelial cells lining the bladder lumen to prevent rupturing during bladder distension. Little is known about Upk1b expression in other normal and malignant tissues. To comprehensively evaluate the potential diagnostic and prognostic utility of Upk1b expression analysis, a tissue microarray containing 14,061 samples from 127 different tumor types and subtypes and 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. Upk1b immunostaining was found in 61 (48%) different tumor types including 50 (39%) with at least one moderately positive and 39 tumor types (31%) with at least one strongly positive tumor. Highest positivity rates were found in urothelial neoplasms (58-95%), Brenner tumors of the ovary (92%), epithelioid mesothelioma (87%), serous carcinoma of the ovary (58%) and the endometrium (53%) as well as in squamous cell carcinoma of the head and neck (18-37%), lung (39%), and esophagus (26%). In urothelial carcinoma, low Upk1b expression was linked to high grade and invasive tumor growth (P < .0001 each) and nodal metastasis (P = .0006). Our data suggest diagnostic applications of Upk1b immunohistochemistry in panels for the distinction of malignant mesothelioma from adenocarcinoma of the lung, urothelial carcinoma from prostatic adenocarcinoma in the bladder, or pancreaticobiliary and gastroesophageal from colorectal adenocarcinoma.

AB - Uroplakin 1B (Upk1b) stabilizes epithelial cells lining the bladder lumen to prevent rupturing during bladder distension. Little is known about Upk1b expression in other normal and malignant tissues. To comprehensively evaluate the potential diagnostic and prognostic utility of Upk1b expression analysis, a tissue microarray containing 14,061 samples from 127 different tumor types and subtypes and 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. Upk1b immunostaining was found in 61 (48%) different tumor types including 50 (39%) with at least one moderately positive and 39 tumor types (31%) with at least one strongly positive tumor. Highest positivity rates were found in urothelial neoplasms (58-95%), Brenner tumors of the ovary (92%), epithelioid mesothelioma (87%), serous carcinoma of the ovary (58%) and the endometrium (53%) as well as in squamous cell carcinoma of the head and neck (18-37%), lung (39%), and esophagus (26%). In urothelial carcinoma, low Upk1b expression was linked to high grade and invasive tumor growth (P < .0001 each) and nodal metastasis (P = .0006). Our data suggest diagnostic applications of Upk1b immunohistochemistry in panels for the distinction of malignant mesothelioma from adenocarcinoma of the lung, urothelial carcinoma from prostatic adenocarcinoma in the bladder, or pancreaticobiliary and gastroesophageal from colorectal adenocarcinoma.

U2 - 10.1016/j.humpath.2022.05.002

DO - 10.1016/j.humpath.2022.05.002

M3 - SCORING: Journal article

C2 - 35550834

VL - 126

SP - 108

EP - 120

JO - HUM PATHOL

JF - HUM PATHOL

SN - 0046-8177

ER -